

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 November 2001 (29.11.2001)




PCT

(10) International Publication Number
WO 01/89456 A2

- (51) International Patent Classification⁷: **A61K** (72) Inventor; and
(75) Inventor/Applicant (for US only): **CLEMENTS, John, D.** [US/US]; 7900 Jeanette Place, New Orleans, LA 98021 (US).
- (21) International Application Number: **PCT/US01/16542**
- (22) International Filing Date: **21 May 2001 (21.05.2001)** (74) Agents: **BALDWIN, Geraldine, F. et al.**; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (25) Filing Language: **English**
- (26) Publication Language: **English** (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (30) Priority Data:
60/205,969 **19 May 2000 (19.05.2000)** **US**
- (71) Applicant (for all designated States except US): **THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND** [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112 (US). (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: **HYBRID LT-A/CT-B HOLOTOXIN FOR USE AS AN ADJUVANT**



(57) Abstract: The present invention provides a novel composition which is a hybrid heat labile enterotoxin comprising the A-subunit of the heat labile toxin of *Escherichia coli* (LT-A) and the B-subunit of the cholera enterotoxin *Vibrio cholerae* (CT-B). The hybrid toxin is designated LT-A/CT-B. The LT-A subunit, the CT-B subunit, or both subunits of the hybrid toxin may be mutant subunits *e.g.*, differing from wild-type subunits by amino acid substitutions, deletions or additions. Also provided are methods of using the novel LT-A/CT-B comprising compositions of the invention as adjuvants for vaccines, methods of making the LT-A/CT-B hybrid holotoxin, and kits.

WO 01/89456 A2



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- without international search report and to be republished upon receipt of that report

HYBRID LT-A/CT-B HOLOTOXIN FOR USE AS AN ADJUVANT

The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require
5 the patent owner to license others on reasonable terms as provided for by the terms of Public Health service grant AI42777 awarded by the National Institute of Allergy and Infectious Disease.

1. FIELD OF THE INVENTION

10 The present invention is directed towards a novel composition which is a hybrid heat labile enterotoxin holotoxin comprising the A-subunit of the heat labile toxin of Escherichia coli (LT-A) and the B-subunit of the cholera enterotoxin of Vibrio cholerae (CT-B). The hybrid toxin is
15 designated LT-A/CT-B. The LT-A subunit, the CT-B subunit, or both subunits of the hybrid holotoxin may be mutant subunits, e.g., differing from wild-type subunits by one or more amino acid substitutions, deletions or additions.

20 2. BACKGROUND OF THE INVENTION

Each year, infectious diseases kill more than 17 million people, including 9 million children. In the United States, deaths due to infectious diseases increased 58
25 percent from 1982 to 1992 and are now third in the leading causes of death. In addition to suffering and death, infectious diseases impose an enormous financial burden on society. The majority of those infections and deaths are caused by organisms that first make contact with and then either colonize or cross mucosal surfaces to infect the host.

30 While vaccination is the most cost-effective means of controlling infectious disease morbidity and mortality, traditional vaccine strategies that involve parenteral

immunization (via needle) with inactivated viruses or bacteria or subunits of relevant virulence determinants of those pathogens do not prevent those interactions. In fact, traditional vaccine strategies do not prevent infection but
5 instead resolve infection before disease ensues. In some cases, HIV for example, once the virus crosses the mucosal surface and enters the host cell, be that a dendritic cell, an epithelial cell, or a T-cell, the host-parasite relationship is moved decidedly in favor of the parasite
10 (HIV). In that case, as in many others, a vaccine strategy that does not prevent the initial infection of the host is unlikely to succeed.

Recently, a great deal of attention has focused on mucosal immunization as a means of inducing secretory IgA (S-
15 IgA) antibodies directed against specific pathogens of mucosal surfaces. The rationale for this is the recognition that S-IgA constitutes greater than 80% of all antibodies produced in mucosal-associated lymphoid tissues in humans and that S-IgA may block attachment of bacteria and viruses,
20 neutralize bacterial toxins, and even inactivate invading viruses inside of epithelial cells. In addition, the existence of a Common Mucosal Immune System permits immunization on one mucosal surface to induce secretion of antigen-specific S-IgA at distant mucosal sites. It is now
25 appreciated that mucosal immunization may be an effective means of inducing not only S-IgA but also systemic antibody and cell-mediated immunity.

The mucosal immune response can be divided into two phases (McGhee and Kiyono 1993, Infect. Agents. Dis. 12:55-
30 73). First, the inductive phase involves antigen presentation and the initiation events which dictate the subsequent immune response. During the initiation events, antigen-specific

lymphocytes are primed and migrate from the inductive sites (e.g., Peyer's patches in the enteric mucosa) through the regional lymph nodes, into the circulation and back to mucosal effector sites (e.g. lamina propria). Once these
5 effector cells have seeded their effector sites, the second phase, or effector phase, of the mucosal immune response can occur. A significant difference between mucosal immunization and parenteral immunization is that both mucosal and systemic immunity can be induced by mucosal immunization while
10 parenteral immunization generally results only in systemic responses.

Most studies on the mucosal immune response conducted to date have dealt with the secretory antibody component of the mucosal response and the complex regulatory
15 issues involved with induction of S-IgA following mucosal immunization and not with the systemic antibody response or cellular immunity induced by mucosal immunization. In that regard, it is important to understand the type of helper T lymphocyte response induced by mucosal immunization since the
20 type of helper T lymphocyte stimulated by an antigen is one of the most important factors for defining which type of immune response will follow. At least two different types of helper T lymphocytes (Th) which can be distinguished based on cytokine secretion have been identified in mice (Cherwinski
25 et al. 1987, Journal of Experimental Medicine 166:1229-1244; Mosmann and Coffman 1989, Annual Reviews of Immunology 7:145-173), humans (Romagnani 1991, Immunology Today 12:256-257) and other animal species (Brown et al. 1994, Infection and Immunity 62:4697-4708). Th1 lymphocytes secrete substantial
30 amounts of IL-2 and IFN-gamma and execute cell-mediated immune responses (e.g. delayed type hypersensitivity and macrophage activation), whereas Th2 lymphocytes secrete IL-4,

IL-5, IL-6 and IL-10 and assist in antibody production for humoral immunity. Theoretically then, antigenic stimulation of one T helper cell subset and not the other would result in production of a particular set of cytokines which would
5 define the resulting immune response.

The presence of these cytokines coupled with an antigenic stimulus presented by macrophages in the context of Class II MHC molecules can initiate a Th1 type responses. The ability of Th1 cells to secrete IL-2 and IFN-gamma further
10 amplifies the response by activating Th1 cells in an autocrine fashion and macrophages in a paracrine fashion. These activated leukocytes can release additional cytokines (e.g., IL-6) which may induce the proliferation and differentiation of antigen specific B lymphocytes to secrete
15 antibody (the effector phase). In this scenario, the predominant isotype secreted by murine B lymphocytes is often IgG2a. In a second scenario (Urban et al. 1992, Immunol. Rev. 127:205-220), antigens such as allergens or parasites can effectively stimulate a Th2 lymphocyte response (the
20 inductive phase). Presentation of such antigens to Th2 cells can result in the production of the lymphokines IL-4 and IL-5 which can induce antigen specific B lymphocytes to secrete IgE and IgG1 or induce eosinophilia, respectively (the effector phase). Furthermore, stimulated Th2 cells can
25 secrete IL-10 which has the ability to specifically inhibit secretion of IL-2 and IFN-gamma by Th1 lymphocytes and also to inhibit macrophage function.

It is obvious that the type of T helper cell stimulated affects the resultant cellular immune response as
30 well as the predominant immunoglobulin isotype secreted. Specifically, IL-4 stimulates switching to the IgE and IgG1 isotypes whereas IFN-gamma stimulates IgG2a secretion.

Numerous studies, predominantly conducted in vitro, have suggested that IL-5, IL-6 and TGF-beta can cause isotype switching to IgA.

5 2.1. BACTERIAL ENTEROTOXINS AS MUCOSAL ADJUVANTS

Despite the attractiveness of mucosal vaccination for inducing both mucosal and systemic immune responses, mucosally administered antigens are frequently not immunogenic. A number of strategies have been developed to
10 facilitate and enhance the immune response obtained after mucosal immunization. Among these strategies are the use of attenuated mutants of bacteria (i.e., *Salmonella* spp.) as carriers of heterologous antigens, encapsulation of antigens into microspheres, gelatin capsules, different formulations
15 of liposomes, adsorption onto nanoparticles, use of lipophilic immune stimulating complexes, and addition of bacterial products with known adjuvant properties. While a number of substances of bacterial origin have been tested as mucosal adjuvants (Lowell et al. 1997, Journal of Infectious
20 Diseases 175:292-301; Roberts et al. 1995, Infection and Immunity 63:2100-2108; Van De Verg et al. 1996, Infection and Immunity 64:5263-5268), the two bacterial proteins with the greatest potential to function as mucosal adjuvants are cholera toxin (CT), produced by various strains of Vibrio
25 cholerae, and the heat-labile enterotoxin (LT) produced by some enterotoxigenic strains of Escherichia coli (Clements et al. 1988, Vaccine 6:269-277; Elson 1989, Immunology Today 146:29-33; Lycke et al. 1992, European Journal of Immunology 22:2277-2281; Xu-Amano et al. 1993, Journal of Experimental
30 Medicine 178:1309-1320).

Although LT and CT have many features in common, these are clearly distinct molecules with biochemical and

immunologic differences which make them unique (see below). Both LT and CT are synthesized as multisubunit toxins with A and B components. On thiol reduction, the A component dissociates into two smaller polypeptide chains. One of
5 these, the A1 piece, catalyzes the ADP-ribosylation of the stimulatory GTP-binding protein (G_s) in the adenylate cyclase enzyme complex on the basolateral surface of the epithelial cell resulting in increasing intracellular levels of cAMP. The resulting increase in cAMP causes secretion of
10 water and electrolytes into the small intestine through interaction with two cAMP-sensitive ion transport mechanisms involving 1) NaCl cotransport across the brush border of villous epithelial cells, and 2) electrogenic Na dependent Cl secretion by crypt cells (Field, 1980, In: Field M, Fordtran
15 JS, Schultz SG, editors. Secretory diarrhea. Baltimore, Md.: Waverly Press. p 21-30). The B-subunit binds to the host cell membrane receptor (ganglioside GM1) and facilitates the translocation of the A-subunit through the cell membrane.

Recent studies have examined the potential of CT
20 and LT to function as mucosal adjuvants against a variety of bacterial and viral pathogens using whole killed organisms or purified subunits of relevant virulence determinants from these organisms. Representative examples include tetanus toxoid (Xu-Amano et al. 1994, Vaccine 12:903-911; Xu-Amano et
25 al. 1993, Journal of Experimental Medicine 178:1309-1320; Yamamoto et al. 1997a, Proceedings of the National Academy of Sciences 94:5267-5272; Yamamoto et al. 1997b, Journal of Experimental Medicine 185:1203-1210), inactivated influenza virus (Gluck et al. 1999, J Virol 73(9):7780-6; Hashigucci et
30 al. 1996, Vaccine 14:113-119; Katz et al. 1996, In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza. III. New York: Elsevier Science. p 292-297; Katz

et al. 1997, Journal of Infectious Diseases 175:352-363;
Komase et al. 1998, Vaccine 16(2-3):248-254), recombinant
urease from Helicobacter spp. (Lee et al. 1995, Journal of
Infectious Diseases 172:161-171; Weltzin et al. 1997, Vaccine
5 4:370-376), pneumococcal surface protein A from Streptococcus
pneumoniae (Wu et al. 1997, Journal of Infectious Diseases
175:839-846), Norwalk virus capsid protein (Mason et al.
1996, Proceedings of the National Academy of Sciences
93:5335-5340), synthetic peptides from measles virus
10 (Hathaway et al. 1995, Vaccine 13:1495-1500), and the HIV-1
peptides (Staats et al. 1996, Journal of Immunology 157:462-
472). There are many other examples and it is clear from
these studies that both LT and CT have significant potential
for use as adjuvants for mucosally (and otherwise)
15 administered antigens. This raises the possibility of an
effective immunization program against a variety of pathogens
involving the administration of killed or attenuated
organisms or relevant virulence determinants of specific
agents in conjunction with LT or CT, preferably mucosally.
20 However, the fact that these toxins stimulate a net luminal
secretory response may prevent their use for practical
vaccine applications. For instance, it was observed that as
little as 5 μ g of purified CT administered orally was
sufficient to induce significant diarrhea in human volunteers
25 while ingestion of 25 μ g of CT elicited a full 20-liter
cholera purge (Levine et al. 1983, Microbiological Reviews
47:510-550).

In recently conducted volunteer studies with LT
administered alone or in conjunction with the *V. cholerae*
30 Whole Cell/B-Subunit Vaccine, LT was shown to induce fluid
secretion at doses as low as 2.5 μ g when administered in
conjunction with the vaccine, while 25 μ g of LT elicited up

to 6-liters of fluid secretion. While the adjuvant effective dose in humans for either of these toxins has not been established, experiments in animals suggest that it may be comparable to the toxic dose. Taken together, these studies suggest that while LT and CT may be attractive as adjuvants, studies in animals do not reflect the full toxic potential of these molecules in humans, and that toxicity may seriously limit their practical use.

10 2.2. DIFFERENCES BETWEEN CT AND LT

As mentioned above, although LT and CT have many features in common, these are clearly distinct molecules with biochemical and immunologic differences which make them unique (Dickinson and Clements, 1996, In: Kiyono H, Ogra PL, McGhee JR, editors. Mucosal Vaccines. San Diego, Calif.: Academic Press. p 73-87). For example, LT has an unusual affinity for carbohydrate containing matrices (Clements and Finkelstein 1979, Infection and Immunity 24:760-769; Clements et al. 1980, Infection and Immunity 24:91-97). LT binds not only to agarose in columns used for purification but, more importantly, to other biological molecules containing galactose, including glycoproteins and lipopolysaccharides. This lectin-like binding property of LT results in a broader receptor population on mammalian cells for LT than for CT which binds only to GM1 (Angstrom et al. 1994, Proc Natl Acad Sci U S A 91(25):11859-63; Clements et al. 1980, Infection and Immunity 24:91-97; Holmgren, 1994, Progress in Brain Research 101:163-177). Moreover, LT and CT generally activate different subsets of T helper cells. CT promotes CD4⁺ Th2-type responses and help for IgG1, IgE and mucosal IgA while LT induces both CD4⁺ Th1- and Th2-type responses and help for IgG1, IgG2a, IgG2b, and mucosal IgA (Marinaro et al. 1995,

Journal of Immunology 155:4621-4629; Xu-Amano et al. 1993, Journal of Experimental Medicine 178:1309-1320). This distinction between LT and CT may be important in terms of selecting a mucosal adjuvant for use with specific categories
5 of pathogens, assuming the Th2 bias holds. Possible sources for this bias include the availability of different receptors for LT and CT, mentioned above, differences in intracellular localization based upon differences in ER-signal sequences between CT and LT, and differences in activation of
10 intracellular signaling pathways. CT, LT strains obtained from human hosts, and LT strains obtained from porcine hosts have -KDEL, -RDEL, and -RDEL, respectively, as ER retention signals.

15 2.3. DEVELOPMENT OF NON-TOXIC MUCOSAL ADJUVANTS

A number of attempts have been made to alter the toxicity of LT and CT, most of which have focused on eliminating enzymatic activity of the A-subunit associated with enterotoxicity. The majority of these efforts have
20 involved the use of site-directed mutagenesis to change amino acids associated with the crevice where NAD binding and catalysis is thought to occur. Recently, a model for NAD binding and catalysis was proposed (Domenighini et al. 1994, Molecular Microbiology 14:41-50; Pizza et al. 1994, Molecular
25 Microbiology 14:51-60) based on computer analysis of the crystallographic structure of LT (Sixma et al. 1993, Journal of Molecular Biology 230:890-918; Sixma et al. 1991, Nature (London) 351:371-377). Replacement of any amino acid in CT or LT involved in NAD-binding and catalysis by site-directed
30 mutagenesis has been shown to alter ADP-ribosyltransferase activity with a corresponding loss of toxicity in a variety of biological assay systems (Burnette et al. 1991, Infection

and Immunity 59:4266-4270; Fontana et al. 1995, Infection and Immunity 63:2356-2360; Harford et al. 1989, European Journal of Biochemistry 183:311-316; Håse et al. 1994, Infection and Immunity 62:3051-3057; Lobet et al. 1991, Infection and
5 Immunity 59:2870-2879; Lycke et al. 1992, European Journal of Immunology 22:2277-2281; Merritt et al. 1995, Nature Structural Biology 2:269-272; Moss et al. 1993, Journal of Biological Chemistry 268:6383-6387; Pizza et al. 1994, Molecular Microbiology 14:51-60; Tsuji et al. 1991, FEBS
10 Letters 291:319-321; Tsuji et al. 1990, Journal of Biological Chemistry 265:22520-22525; Yamamoto et al. 1997a, Proceedings of the National Academy of Sciences 94:5267-5272; Yamamoto et al. 1997b, Journal of Experimental Medicine 185:1203-1210). The adjuvanticity potential of some of these mutants has been
15 tested on animal models using a variety of coadministered antigens (DiTommaso et al. 1996, Infection and Immunity 64:974-979; Lycke et al. 1992, European Journal of Immunology 22:2277-2281; Partidos et al. 1996, Immunology 89:483-487; Yamamoto et al. 1997a, Proceedings of the National Academy of
20 Sciences 94:5267-5272; Yamamoto et al. 1997b, Journal of Experimental Medicine 185:1203-1210). In addition, it has been shown that exchanging K for E112 in LT not only removes ADP-ribosylating enzymatic activity, but cAMP activation and adjuvant activity as well (Lycke et al. 1992, European
25 Journal of Immunology 22:2277-2281). A logical conclusion from the Lycke et al. studies is that ADP-ribosylation and induction of cAMP are essential for the adjuvant activity of these molecules. As a result, a causal linkage has been established between adjuvanticity and enterotoxigenicity. That
30 is, the accumulation of cAMP responsible for net ion and fluid secretion into the gut lumen was thought to be a requisite to adjuvanticity (see below).

Dickinson and Clements (Dickinson and Clements, 1995, Infection and Immunity 63:1617-1623) explored an alternate approach to dissociation of enterotoxicity from adjuvanticity. Like other bacterial toxins that are members
5 of the A-B toxin family, both CT and LT require proteolysis of a trypsin sensitive bond to become fully active. In these two enterotoxins, that trypsin sensitive peptide is subtended by a disulfide interchange that joins the A1 and A2 pieces of the A-subunit. In theory, if the A1 and A2 pieces cannot
10 separate, A1 may not be able to find its target (adenylate cyclase) on the basolateral surface or may not assume the conformation necessary to bind or hydrolyze NAD.

Dickinson and Clements constructed a mutant of LT using site-directed mutagenesis to create a single amino acid
15 substitution within the disulfide subtended region of the A subunit separating A1 from A2. This single amino acid change altered the proteolytically sensitive site within this region, rendering the mutant insensitive to trypsin activation. The physical characteristics of this mutant were
20 examined by SDS-PAGE, its biological activity was examined on mouse Y-1 adrenal tumor cells and Caco-2 cells, its enzymatic properties determined in an in vitro NAD:agmatine ADP-ribosyltransferase assay, and its immunogenicity and immunomodulating capabilities determined by testing for the
25 retention of immunogenicity and adjuvanticity. This mutant LT, designated LT(R192G), has been shown to be an effective mucosal adjuvant and has recently been evaluated in a series of Phase I safety studies. LT(R192G) is the subject of United States Patent No. 6,019,982 (Mutant enterotoxin effective as
30 a non-toxic oral adjuvant). Clements also constructed a double-mutant LT, LT(R192G/L211A), which has even further reduced toxicity (United States Patent No. 6,033,673).

Tsuji et al. (Tsuji et al. 1997, Immunology 90:176-182) recently demonstrated that a protease-site deletion mutant LT(Δ 192-194) also lacks in vitro ADP-ribosylagmatine activity, has a ten-fold reduction in enterotoxicity in 5 rabbit ligated ileal loops, and a 50% reduction and delayed onset of cAMP induction in cultured myeloma cells. LT(Δ 192-194) was shown to have increased adjuvant activity for induction of serum IgG and mucosal IgA against measles virus when compared to native LT, LT-B, or LT(E112K). LT(Δ 192-194) 10 was effective when administered intranasally, subcutaneously, intraperitoneally, or orally, although mucosal IgA responses were only demonstrated following mucosal administration. These investigators also demonstrated increased adjuvant activity for mucosally administered LT(Δ 192-194) in 15 conjunction with KLH, BCG, and Ova.

Other mutants have also been created and tested. The first of those is the active-site mutant of LT designated LT(S63K) developed by Rappuoli and colleagues (Pizza et al. 1994, Molecular Microbiology 14:51-60) and the second is the 20 CT active-site mutant CT (S61F) developed by McGhee and colleagues (Yamamoto et al. 1997a, Proceedings of the National Academy of Sciences 94:5267-5272; Yamamoto et al. 1997b, Journal of Experimental Medicine 185:1203-1210). LT(S63K) was one of a group of LT A-subunit mutants shown to 25 be devoid of biological activity on mouse Y-1 adrenal tumor cells and to lack detectable in vitro ADP-ribosyltransferase activity. LT(S63K) has been shown to be able to enhance production of anti-Ovalbumin (Ova) IgG in the sera and, to a lesser extent, anti-Ova IgA in vaginal secretions of mice 30 immunized intranasally with up to five immunizations consisting of Ova combined with LT(S63K) (DiTommaso et al. 1996, Infection and Immunity 64:974-979). One publication

(Partidos et al. 1996, Immunology 89:483-487) and a number of abstracts presented at various scientific meeting have further characterized this molecule as having intranasal adjuvanticity when administered with other antigens. Oral
5 adjuvanticity for LT(S63K) has not been clearly established.

In two recent papers by Yamamoto et al. (Yamamoto et al. 1997a, Proceedings of the National Academy of Sciences 94:5267-5272; Yamamoto et al. 1997b, Journal of Experimental Medicine 185:1203-1210), mutants of CT with mutations in the
10 NAD binding site that lack detectable in vitro ADP-ribosyltransferase activity and enterotoxicity and fail to induce cAMP accumulation in CHO cells were examined for parenteral and mucosal adjuvanticity. In the first study, these investigators demonstrated that CT(E112K) and CT(S61F)
15 retained adjuvanticity for Ova when administered subcutaneously. CT-B alone did not function as an adjuvant, indicating that some portion of the A-subunit must be present for adjuvant activity. Both mutant CTs induced Ova specific CD4+ T-cell proliferative responses with subsequent
20 production of IL-4, IL-5, IL-6 and IL-10 (Th2 type cytokines) comparable to native CT. Significantly, neither native CT nor the mutant CTs promoted Th1 type cytokine development. Importantly, in these studies CT(E112K) exhibited adjuvant activity whereas LT(E112K) had previously been shown not to
25 possess adjuvant activity (Lycke et al. 1992, European Journal of Immunology 22:2277-2281). One possible explanation for this difference in findings is that CT(E112K) was administered subcutaneously while LT(E112K) was administered orally. Alternatively, this may reflect inherent differences
30 between CT and LT. In the second paper by Yamamoto et al., mice were immunized intranasally with CT(S61F) in conjunction with Ova, tetanus toxoid (TT), or influenza virus. Mice

showed antigen-specific increases in serum antibodies as well as significant increases in antigen-specific antibodies in nasal and vaginal washes, saliva and fecal extracts that were comparable to those obtained with native CT. Again, CT-B
5 failed to function as an adjuvant when administered intranasally. Both CT(S61F) and native CT elicited Th2 type cytokine secretion and cytokine mRNAs, but not Th1 type cytokine responses.

10 2.4. MECHANISMS OF ADJUVANTICITY

There are a number of potential cellular targets for these bacterially derived adjuvants and the precise mechanism of action remains to be determined. Clearly, significant efforts have been expended to resolve this
15 (Bromander et al. 1993, Scandinavian Journal of Immunology 37:452-458; Cebra et al. 1986, In: Brown F, Channok RM, Lerner RA, editors. Vaccines 86: New approaches to immunization. Developing vaccines against parasitic, bacterial, and viral diseases: Cold Spring Harbor, N.Y. p
20 129-133; Clarke et al. 1991, Immunology 72:323-328; Clements et al. 1988, Vaccine 6:269-277; Elson 1989, Immunology Today 146:29-33; Elson and Ealding 1984a, Journal of Immunology 133:2892-2897; Elson and Ealding 1984b, Journal of Immunology 132:2736-2741; Elson et al. 1995, Journal of Immunology
25 154:1032-1040; Hornquist and Lycke 1993, European Journal of Immunology 23:2136-2143; Lycke et al. 1991; Nedrud and Sigmund 1991, Reg. Immunol. 3:217-222; Snider et al. 1994, Journal of Immunology 53:647-657; Takahashi et al. 1996, Journal of Infectious Diseases 173:627-635; Xu-Amano et al.
30 1994, Vaccine 12:903-911; Xu-Amano et al. 1993, Journal of Experimental Medicine 178:1309-1320). Several models have been proposed, none of which is completely satisfactory. A

summary of these proposed mechanisms is found in the review by Freytag and Clements (Freytag and Clements, 1999, Curr Top Microbiol Immunol 236:215-36). Rather than a single defined mechanism, adjuvanticity should be viewed as an outcome and
5 not an event. It is likely to be some combination of effects that collectively results in the observed outcome known as enhanced immunity or adjuvanticity. It is also important to note that most studies attempting to define the mechanism of adjuvanticity of CT and LT focus on induction of sIgA and Th2
10 events as the only or most relevant outcomes, ignoring the Th1 induction potential of LT which is likely to be important for protection against intracellular bacterial pathogens and viruses.

15 2.5. ROLE OF cAMP IN ADJUVANTICITY

The role of cAMP in the adjuvanticity of CT, LT, and mutants of CT and LT remains controversial, in part because different mutants of LT and CT have been evaluated using varying techniques in different laboratories and in
20 part because different routes of administration (i.e., intranasal, oral) have been employed with various antigens. A recent report by Cheng et al. (Cheng et al. 1999, Vaccine 18(1-2):38-49) provided a side-by-side comparison of LT, active-site mutants, the protease-site mutant LT(R192G), and
25 recombinant B-subunit for the ability to induce specific, targeted immunologic outcomes using a single, defined antigen (Tetanus Toxoid) following two different mucosal routes of immunization (intranasal or oral). For this study, these investigators employed the Y-1 Adrenal Tumor Cell assay, a
30 non-polarized Caco-2 cell assay for induction of cAMP, the Patent Mouse assay for enterotoxicity (Guidry et al., Infect. And Immun., 1997, 65(12):4943-4950), and an in vitro antigen

restimulation assay on splenic mononuclear cells for determination of Th1 and Th2 type cytokine production. The Patent Mouse assay is a modification of the sealed adult mouse assay of Richardson et al. (Richardson et al. 1984, 5 Infection and Immunity 43:482-486). It is slightly less sensitive than the more traditional Rabbit Ligated Ileal Loop assay, but responds to native LT and CT in a dose dependent fashion. In those studies, following intranasal immunization, both Th1 and Th2 type cellular immune responses 10 to TT differed for the various active site mutants and LT-B and were dependent upon their ability to induce cAMP. For example, despite the fact that LT-B given intranasally can induce serum IgG, it is not able to induce any significant level of T cell response. Furthermore, while all active site 15 mutants examined were able to induce antigen-specific antibody responses when administered intranasally, only native LT, LT(A69G), and LT(R192G), which retained the ability to induce production of cAMP, were able to elicit antigen-specific Th1 and Th2 cytokines following intranasal 20 immunization in combination with TT. As with intranasal immunization, production of both Th1 and Th2-type cytokines following oral immunization was correlated with the ability to induce accumulation of cAMP.

Recently, Giuliani et al. (Giuliani et al. 1998, J 25 Exp Med 187(7):1123-32) compared two active-site mutants, LT(S63K) and LT(A72R), for the ability to function as intranasal adjuvants. In those studies, LT(A72R) which retains some level of enzymatic activity was a better intranasal adjuvant for ovalbumin than LT(S63K) which those 30 authors have reported to lack any detectable enzymatic activity. It remains to be seen whether LT(A72R) induces

antigen-specific cytokine responses or functions orally in animals or humans.

Both CT and LT have significant potential to function as mucosal adjuvants for co-administered antigens and to facilitate the development of entire new classes of vaccines for mucosal delivery. The data reported by Cheng et al. makes it clear that different mutants of LT have different properties that vary depending upon the nature of the mutation and the route of delivery. Specifically, those mutants that retain the ability to induce cAMP elicit quantitatively and qualitatively different responses than do those mutants that lack this function. For induction of antigen-specific antibody responses, it appears that any of the mutants examined in Cheng et al. will suffice if delivered intranasally. Clearly, the best cellular responses are elicited by native LT and mutants that retain some cAMP activity and only those that retain some cAMP activity can elicit Th1 type responses when administered orally. Significant serum antigen-specific IgG responses following oral administration were only observed for these mutants as well, and not for those that lacked the ability to induce cAMP.

2.6. ANALYSIS OF HYBRID TOXINS

One recent study has employed hybrid toxins to explore the differential toxicity of CT and LT (Rodighiero et al. 1999, J Biol Chem 274(7):3962-9; Rodighiero et al. 1998, Biochem Soc Trans 26(4):S364). In those studies, hybrid toxins were constructed in which the A1 fragment of one toxin was substituted for that of the other (CT-A1:LT-A2^{REDL}/LT-B; LT-A1:CT-A2^{KDEL}/CT-B) as well as hybrids in which the putative ER-retention signal was altered (CT-A1:CT-A2^{RDEL}/CT-

B; CT-A1:CT-A2^{RDEL}/LT-B). (Importantly, an LT-A/CT-B hybrid was neither created nor evaluated in these studies). The findings from these hybrid toxin studies are 1) CT-A1:LT-A2^{RDEL}/LT-B is less potent than wild type CT at inducing
5 chloride secretion; 2) LT-A1:CT-A2^{KDEL}/CT-B induced chloride secretion at levels comparable to levels induced by wild type CT; 3) all of the constructs containing CT-A1 had equivalent ADP-ribosyltransferase activity; 4) wild type LT and LT-A1:CT-A2^{KDEL}/CT-B had higher activity than native CT, and 5)
10 the differences between the toxicities of CT and LT are not a function of differences in the ER retention signals. The third hybrid, CT-A1:CT-A2^{RDEL}/LT-B, induced chloride secretion at levels equivalent to wild type CT.

One other hybrid toxin study has been reported
15 (Takeda et al. 1981, Infect Immun 34(2):341-6). In that study, LT-A/CT-B and CT-A/LT-B hybrids were prepared by dissociation:re-association chromatography (i.e., the hybrids were not produced recombinantly from an organism designed to express LT-A and CT-B in the absence of LT-B and CT-A, but,
20 instead, were prepared by isolating wild-type LT and CT holotoxin and dissociating said holotoxins into their substituent subunits and then reassembling a hybrid holotoxin by combining the CT-B subunits with the LT-A subunits). The hybrids were reported to have toxicity similar to that of the
25 parent proteins from which the A subunits were derived.

Citation or identification of any reference in any section of this application shall not be construed as an admission that such reference is available as prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention provides a composition comprising an LT-A/CT-B hybrid enterotoxin holotoxin, which holotoxin has immunologic adjuvant activity and is
5 substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the patent mouse assay.

Also provided is a composition useful in producing a protective immune response to a pathogen in a host comprising an admixture of an effective amount of an antigen
10 and an adjuvant effective amount of a composition comprising an LT-A/CT-B hybrid enterotoxin holotoxin, which holotoxin has immunologic adjuvant activity and is substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the patent mouse assay.

15 Also provided is a kit useful in producing a protective immune response in a host to a pathogen comprising two components: (a) an effective amount of antigen and (b) an adjuvant effective amount of an LT-A/CT-B hybrid enterotoxin holotoxin, which holotoxin has immunologic adjuvant activity
20 and is substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the patent mouse assay.

The present invention also provides a method of creating or sustaining a protective or adaptive immune
25 response to an antigen in a host comprising administering an admixture of an effective amount of an antigen and an adjuvant effective amount of an LT-A/CT-B hybrid enterotoxin holotoxin, which holotoxin has immunologic adjuvant activity and is substantially less toxic than native *E. coli* heat-
30 labile enterotoxin holotoxin as measured in the patent mouse assay, in an orally acceptable pharmaceutical carrier.

The present invention also provides a method of inducing a protective immune response to an antigen in a host comprising administering an effective amount of an antigen in conjunction with an adjuvant effective amount of an LT-A/CT-B hybrid enterotoxin holotoxin, which holotoxin has immunologic adjuvant activity and is substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the patent mouse assay.

Also provided is a method of inducing a protective immune response against an enterotoxic bacterial organism comprising administering an adjuvant effective amount of an LT-A/CT-B hybrid enterotoxin holotoxin, which holotoxin has immunologic adjuvant activity and is substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the patent mouse assay, as a component of a vaccine directed against the enterotoxic bacterial organism.

The present invention is based, in part, on the observation that a hybrid toxin molecule, designated LT-A/CT-B, consisting of the A-subunit of the heat labile toxin of *Escherichia coli* (LT-A) and the B-subunit of the cholera enterotoxin of *Vibrio cholerae* (CT-B) has significantly and unexpectedly reduced enterotoxicity and enzymatic activity when compared to either native LT or native CT and yet retains the adjuvant properties of native LT for induction of humoral and cellular immune responses to a co-administered antigen. These findings are in contrast to the findings of Takeda et al. (Takeda et al. 1981, Infect Immun 34(2):341-6) in which hybrid toxin molecules were found to have toxicity equivalent to the parent proteins from which the A-subunits were generated, and the findings of Rodighiero et al. (Rodighiero et al. 1999, J Biol Chem 274(7):3962-9; Rodighiero et al. 1998, Biochem Soc Trans 26(4):S364) in

which a hybrid, LT-A1:CT-A2^{KDEL}/CT-B, induced chloride secretion at levels comparable to levels induced by wild type CT. In neither of those studies was adjuvanticity of the hybrid molecules examined. Indeed, based upon these published
5 findings (Rodighiero et al. 1999, *J Biol Chem* 274(7):3962-9; Rodighiero et al. 1998, *Biochem Soc Trans* 26(4):S364; Takeda et al. 1981, *Infect Immun* 34(2):341-6), one skilled in the art would predict that LT-A/CT-B would retain full enzymatic activity and enterotoxigenicity.

10 The reduction in enzymatic activity and toxicity of the present novel hybrid LT-A/CT-B when compared with native LT and native CT is also surprising in that it is not necessary to mutate or alter the A-subunit of the holotoxin. Previous studies have shown that alteration, by site-directed
15 mutagenesis, of amino acids in CT or LT involved in NAD-binding and catalysis alters ADP-ribosyltransferase activity with a corresponding loss of toxicity in a variety of biological assay systems (Burnette et al. 1991; Fontana et al. 1995, *Infection and Immunity* 63:2356-2360; Harford et al.
20 1989, *European Journal of Biochemistry* 183:311-316; Häse et al. 1994, *Infection and Immunity* 62:3051-3057; Lobet et al. 1991, *Infection and Immunity* 59:2870-2879; Lycke et al. 1992, *European Journal of Immunology* 22:2277-2281; Merritt et al. 1995, *Nature Structural Biology* 2:269-272; Moss et al. 1993,
25 *Journal of Biological Chemistry* 268:6383-6387; Pizza et al. 1994, *Molecular Microbiology* 14:51-60; Tsuji et al. 1991, *FEBS Letters* 291:319-321; Tsuji et al. 1990, *Journal of Biological Chemistry* 265:22520-22525; Yamamoto et al. 1997a, *Proceedings of the National Academy of Sciences* 94:5267-5272;
30 Yamamoto et al. 1997b, *Journal of Experimental Medicine* 185:1203-1210). The LT-A/CT-B hybrid that is one embodiment of the current invention has an unaltered LT-A subunit and

therefore there is no reason, *a priori*, for one to expect the LT-A/CT-B hybrid to have reduced enzymatic activity or enterotoxicity. Indeed, the contrasting, inverse hybrid CT-A/LT-B has undiminished toxicity and enzymatic activity when
5 compared to native LT and CT.

With respect to adjuvanticity, despite the significant and surprising reduction in enterotoxicity and enzymatic activity, the novel hybrid of the present invention retains the ability to function as a mucosal adjuvant for a
10 co-administered antigen.

LT-A/CT-B hybrids in which the A subunit is a mutant subunit, for example, LT-A(R192G), have even further reduced toxicity when compared to the non-hybrid LT-A(R192G)/LT-B holotoxin. Thus, a further object of the
15 present invention is to reduce the toxicity of any LT-A molecule, either wild-type or mutant, by providing a hybrid holotoxin comprising the mutant LT-A and CT-B.

The present invention provides a method for reducing the enterotoxic potential of LT and CT, thereby
20 providing a safety window for use of these molecules as immunologic adjuvants.

The invention also provides a composition useful in these methods. The composition comprises an effective amount of LT-A/CT-B in combination with an effective amount of
25 antigen.

Also provided are methods of using LT-A/CT-B as an adjuvant for the stimulation of an immune response against an antigen administered in combination with the novel adjuvant.

30 4. BRIEF DESCRIPTION OF THE FIGURES

The present invention may be understood more fully by reference to the following detailed description of the

invention, examples of specific embodiments of the invention and the appended figures in which:

Figure 1 is a schematic diagram of the plasmid pLT-A/CT-B, which encodes LT-A and CT-B under the control of the lac promoter and also depicts plasmid pCT-A/LT-B which encodes CT-A and LT-B under the control of the lac promoter. Figure 1 also depicts the sequences used to construct pLT-A/CT-B and pCT-A/LT-B, a key for said sequences follows:

- | | | |
|----|------------|---|
| 10 | pBB6 | 5.1 kb PstI-EcoRI fragment of plasmid pBB6 containing intact ctx and zot genes cloned into pBR322 |
| | pCT2 | 5.1 kb PstI-EcoRI fragment of plasmid pCT2 containing intact ctx and zot genes cloned into |
| 15 | | pUC19 |
| | pCTA3 | 1kb Eco-RI-SstI fragment subcloned from pCT2 into pUC18 following PCR introduction of EcoRI and SstI restriction sites upstream and downstream, respectively, of ctxa and ctxb. |
| 20 | pCS96 | 1.5 kb EcoRI-HindIII fragment of plasmid pCS96 containing intact ltx genes cloned into pUC18. |
| | pCT-A/LT-B | 1.5 kb EcoRI-HindIII fragment of plasmid pCT-A/LT-B containing intact ctxa and ltxb genes cloned into pUC18. |
| 25 | pCTB5 | Sst-EcoRI fragment subcloned from pCT2 and pUC18 following PCR introduction of SstI restriction site upstream of ctxb. |
| | pLT-A/CT-B | 1.5 kb EcoRI-HindIII fragment of plasmid pLT-A/CT-B containing intact ltxa and ctxb genes |
| 30 | | cloned into pUC18. |

Figure 2 is a graphical representation of results from a patent mouse intestinal assay demonstrating that LT-A/CT-B and LT-A(R192G)/CT-B have reduced enterotoxicity when compared to native LT, CT, LT(R192G) or CT-A/LT-B, and that
5 LT-A(R192G)/CT-B has reduced toxicity when compared to LT-A/CT-B. Groups of mice were orally inoculated with LT, CT, CT-A/LT-B, or LT-A/CT-B at 5, 25, or 125 μ g. Following a three hour interval, the gut:carcass ratio of each animal was determined. The gut-carcass ratio is defined as the
10 intestinal weight divided by the remaining carcass weight. There were three animals per group and the means for each data point are shown.

Figure 3 depicts the results of a cAMP assay demonstrating that LT-A/CT-B has significantly reduced enzymatic activity
15 when compared to native LT, CT, or CT-A/LT-B.

Figure 4 depicts a comparison of the abilities of LT-A/CT-B, native LT, native CT, and CT-A/LT-B to induce antigen-specific antibody responses following mucosal immunization
20 with Tetanus Toxoid in conjunction with either LT-A/CT-B, native LT, native CT, or CT-A/LT-B. LT-A/CT-B was as effective as native LT, native CT, or CT-A/LT-B in inducing antigen-specific antibody responses in immunized animals, despite the significantly reduced enterotoxicity and
25 enzymatic activity of LT-A/CT-B when compared to native LT, native CT, or CT-A/LT-B.

Figure 5 depicts the results of a comparison of LT-A/CT-B with native LT, native CT, and CT-A/LT-B for their ability to
30 enhance production of antigen-specific Th1-type cytokines; specifically, IFN-gamma, by mononuclear cells from the spleens of immunized animals. LT-A/CT-B was as effective as

native LT, and more effective than native CT, or CT-A/LT-B in inducing antigen-specific IFN-gamma in immunized animals, despite the significantly reduced enterotoxicity and enzymatic activity of LT-A/CT-B when compared to native LT,
5 native CT, or CT-A/LT-B.

Figure 6 depicts a comparison of LT-A/CT-B with native LT, native CT, and CT-A/LT-B for the ability to enhance production of antigen-specific Th2-type cytokines; specifically, IL-6, by mononuclear cells from the spleens of
10 immunized animals. LT-A/CT-B was more effective than native LT, native CT, or CT-A/LT-B in inducing antigen-specific IL-6 in immunized animals, despite the significantly reduced enterotoxicity and enzymatic activity of LT-A/CT-B when
15 compared to native LT, native CT, or CT-A/LT-B.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention encompasses a composition and methods for its use to promote the production of serum and/or mucosal antibodies as well as cell-mediated immune responses
20 against antigens that are simultaneously administered with a hybrid bacterial toxin. The hybrid toxin combines the A-subunit of the heat-labile enterotoxin of Escherichia coli (LT-A) with the B-subunit of the cholera enterotoxin of Vibrio cholerae (CT-B). This hybrid molecule has unexpectedly
25 reduced enterotoxicity and enzymatic activity yet retains its ability to act as an immunological adjuvant. The invention is based, in part, on the discovery that LT-A/CT-B has utility as an adjuvant. LT-A/CT-B can be administered in any manner known to those of skill in the art, preferably by mucosal,
30 for example but not limited to oral, administration. The mode of administration may be mucosal (i.e., intranasal, oral, rectal) or parenteral (i.e., subcutaneous,

intramuscular, intradermal, intravenous, intraperitoneal). Administration results in the production of antibodies as well as cell-mediated immune responses against the antigens with which LT-A/CT-B is delivered.

5 Hybrids consisting of the A-subunit of one toxin combined with the B-subunit of the other toxin were constructed. It was unexpectedly found that LT-A/CT-B has significantly reduced enterotoxicity in the patent mouse
10 hybrid CT-A/LT-B. In order to more fully evaluate this unexpected finding, LT-A/CT-B was evaluated for the ability to induce cAMP in cultured Caco2 cells. Activity in this assay has been shown to be directly correlated with the toxicity of these molecules. Despite having an unaltered,
15 intact A-subunit, the hybrid molecule LT-A/CT-B induced significantly less cAMP in this assay when compared to native LT, native CT, or the alternate hybrid CT-A/LT-B.

 As described above, an unexpected finding was that LT-A/CT-B has significantly reduced toxicity and enzymatic
20 activity despite having an unmodified LT-A subunit. Also, surprisingly, even when the LT-A subunit is modified (for example, when the LT-A subunit has an R192G mutation), the hybrid LT-A/CT-B has even less toxicity than the non-hybrid LT with that same mutation, e.g., LT-A(R192G)/CT-B has
25 reduced toxicity as compared to LT-A(R192G)/LT-B. Thus, the present invention also encompasses LT-A/CT-B hybrid toxins, wherein the LT-A subunit, the CT-B subunit, or both subunits of the hybrid toxin are mutant subunits, e.g., differing from wild-type subunits by one or more amino acid substitutions,
30 deletions or additions. Suitable mutant LT-A subunits include LT-A(R192G), LT-A(R192G/L211A), LT-A(S63K), LT-A(E112K), LT-A(Δ 192-194), LT-A(A69G) and LT-A(A72R). The use of hybrids

containing mutant, detoxified LT-A subunits provides the advantage of two separate means for reducing the toxicity of the LT-A/CT-B hybrid. The mutation of LT-A alone renders the molecule safe for administration; when combined with CT-B to
5 form a hybrid, the resulting molecule can be even less toxic because both the mutation of LT-A and the association of LT-A with CT-B reduce toxicity. In addition, the use of mutant CT-B subunits is also encompassed.

The present invention supersedes the prior art in
10 that LT-A/CT-B retains adjuvantivity for induction of antigen-specific antibody and cell mediated immune responses against a co-administered antigen. In the illustrative example presented in section 6, LT-A/CT-B induces antigen-specific Th1 type responses equivalent to those induced by
15 native LT and significantly greater than those induced by native CT or the alternate hybrid CT-A/LT-B. Furthermore, LT-A/CT-B induces antigen-specific Th2 type responses greater than those induced by native LT, native CT or the alternate hybrid CT-A/LT-B.

20 The present invention also provides a method of producing LT-A/CT-B comprising the steps of

a) culturing a cell comprising a vector capable of expressing in said cell an LT-A subunit and culturing a cell comprising a
25 vector capable of expressing in said cell a CT-B subunit, but not capable of expressing an LT-B subunit or a CT-A subunit under conditions that allow for the expression by said cell or cells of
30 said LT-A and CT-B molecules, and

b) isolating the LT-A/CT-B produced by the cell or cells.

It will be apparent to the skilled artisan that both subunits may be produced in one cell from one vector, or
5 in one cell from two different vectors, or in different cells from two different vectors.

Preferably the cell is a bacterial cell, most preferably an E. coli cell, and the vector is a plasmid.

Variations of this method include separate
10 expression and isolation of the LT-A and CT-B subunits from different cell cultures and subsequent association of said subunits to form LT-A/CT-B, and methods wherein the LT-A subunit, the CT-B subunit, or both subunits are mutant subunits.

15

5.1 PRODUCTION OF LT-A/CT-B

LT-A/CT-B can be produced by a number of means apparent to those of skill in the art. For example, plasmid pLT-A/CT-B, fully described in Example 6.1, can be utilized
20 to produce substantially pure LT-A/CT-B in *E. coli*. LT-A/CT-B can be isolated by agarose affinity chromatography from bacteria expressing an LT-A/CT-B encoding plasmid. Alternate methods of purification will be apparent to those skilled in the art.

25 The LT-A/CT-B of the present invention is preferably isolated LT-A/CT-B. As used herein, an "isolated" LT-A/CT-B means LT-A/CT-B separated from that which it is normally associated, or separated from the material normally present during the production of LT-A/CT-B by a cell. More
30 preferably, the LT-A/CT-B is substantially purified, i.e., LT-A/CT-B is 5%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%

or 99% of the total protein present in an LT-A/CT-B comprising preparation.

5.2 MODE OF ADMINISTRATION OF LT-A/CT-B
AND UNRELATED ANTIGENS

5

In accordance with the present invention, LT-A/CT-B can be administered in conjunction with any biologically relevant antigen and/or vaccine, such that an increased immune response, as compared to the immune response achieved by administration of said antigen and/or vaccine without LT-A/CT-B, to said antigen and/or vaccine is achieved. In a preferred embodiment, LT-A/CT-B and antigen are administered simultaneously in a pharmaceutical composition comprising an effective amount of LT-A/CT-B and an effective amount of antigen. The mode of administration is mucosal (i.e., intranasal, oral, rectal) or parenteral (i.e., subcutaneous, intramuscular, intradermal, intravenous, intraperitoneal). The respective amounts of LT-A/CT-B and antigen will vary depending upon the identity of the route of administration, antigen employed and the species of animal to be immunized. In one embodiment, the initial administration of LT-A/CT-B and antigen is followed by a boost of the relevant antigen. In another embodiment no boost is given. The timing of boosting may vary, depending on the route, antigen and the species being treated. The modifications in route, dosage range and timing of boosting for any given species and antigen are readily determinable by routine experimentation. The boost may be of antigen alone or in combination with LT-A/CT-B.

30

The methods and compositions of the present invention are intended for use both in immature and mature vertebrates, in particular birds and mammals, including but

- not limited to humans. Useful antigens, as examples and not by way of limitation, include antigens from pathogenic strains of bacteria (Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis,
5 Corynebacterium diphtheriae, Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella ozaenae, Klebsiella rhinoscleromatis, Staphylococcus aureus, Vibrio cholerae, Escherichia coli, Pseudomonas aeruginosa,
10 Campylobacter jejuni, Aeromonas hydrophila, Bacillus cereus, Edwardsiella tarda, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Salmonella typhimurium, Treponema pallidum, Treponema pertenuis, Treponema caratense, Borrelia
15 vincentii, Borrelia burgdorferi, Leptospira icterohemorrhagiae, Mycobacterium tuberculosis, Toxoplasma gondii, Pneumocystis carinii, Francisella tularensis, Brucella abortus, Brucella suis, Brucella melitensis, Mycoplasma spp., Rickettsia prowazekii, Rickettsia
20 tsutsugamushi, Chlamydia spp., Helicobacter pylori);
pathogenic fungi (Coccidioides immitis, Aspergillus fumigatus, Candida albicans, Blastomyces dermatitidis, Cryptococcus neoformans, Histoplasma capsulatum); protozoa
(Entamoeba histolytica, Trichomonas tenax, Trichomonas
25 hominis, Trichomonas vaginalis, Trypanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Plasmodium vivax, Plasmodium
falciparum, Plasmodium malariae); or Helminths (Enterobius
30 vermicularis, Trichuris trichiura, Ascaris lumbricoides, Trichinella spiralis, Strongyloides stercoralis, Schistosoma japonicum, Schistosoma mansoni, Schistosoma haematobium, and

hookworms) either presented to the immune system in whole cell form or in part isolated from media cultures designed to grow said organisms which are well know in the art, or protective antigens from said organisms obtained by genetic
5 engineering techniques or by chemical synthesis.

Other relevant antigens would be from pathogenic viruses (as examples and not by limitation: Poxviridae, Herpesviridae, Herpes Simplex virus 1, Herpes Simplex virus 2, Adenoviridae, Papovaviridae, Enteroviridae,
10 Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza viruses, parainfluenza viruses, mumps, measles, respiratory syncytial virus, rubella, Arboviridae, Rhabdoviridae, Arenaviridae, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis E virus, Non-A/Non-B
15 Hepatitis virus, Rhinoviridae, Coronaviridae, Rotoviridae, and Human Immunodeficiency Virus) either presented to the immune system in whole or in part isolated from media cultures designed to grow such viruses which are well known in the art or protective antigens therefrom obtained by
20 genetic engineering techniques or by chemical synthesis.

Further examples of relevant antigens include, but are not limited to, vaccines. Examples of such vaccines include, but are not limited to, influenza vaccine, pertussis vaccine, diphtheria and tetanus toxoid combined with
25 pertussis vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, hepatitis E vaccine, Japanese encephalitis vaccine, herpes vaccine, measles vaccine, rubella vaccine, mumps vaccine, mixed vaccine of measles, mumps and rubella, papillomavirus vaccine, parvovirus
30 vaccine, respiratory syncytial virus vaccine, Lyme disease vaccine, polio vaccine, malaria vaccine, varicella vaccine, gonorrhea vaccine, schistosomiasis vaccine, rotavirus

vaccine, mycoplasma vaccine pneumococcal vaccine, meningococcal vaccine, Campylobacter vaccine, Helicobacter vaccine, cholera vaccine, enterotoxigenic E. coli vaccine, enterohemorrhagic E. coli vaccine, Shigella vaccine, 5 Salmonella vaccine and others. These can be produced by known common processes. In general, such vaccines comprise either the entire organism or virus grown and isolated by techniques well known to the skilled artisan or comprise relevant antigens of these organisms or viruses which are produced by 10 genetic engineering techniques or chemical synthesis. Their production is illustrated by, but not limited to, as follows:

Influenza vaccine: a vaccine comprising the whole or part of hemagglutinin, neuraminidase, nucleoprotein and matrix protein which are obtainable by purifying a virus, 15 which is grown in embryonated eggs, with ether and detergent, or by genetic engineering techniques or chemical synthesis.

Pertussis vaccine: a vaccine comprising the whole or a part of pertussis toxin, hemagglutinin and K-agglutinin which are obtained from avirulent toxin with formalin which 20 is extracted by salting-out or ultracentrifugation from the culture broth or bacterial cells of *Bordetella pertussis*, or by genetic engineering techniques or chemical synthesis.

Diphtheria and tetanus toxoid combined with pertussis vaccine: a vaccine mixed with pertussis vaccine, 25 diphtheria and tetanus toxoid.

Japanese encephalitis vaccine: a vaccine comprising the whole or part of an antigenic protein which is obtained by culturing a virus intracerebrally in mice and purifying the virus particles by centrifugation or ethyl alcohol and 30 inactivating the same, or by genetic engineering techniques or chemical synthesis.

Hepatitis B vaccine: a vaccine comprising the whole or part of an antigen protein which is obtained by isolating and purifying the HBs antigen by salting-out or ultracentrifugation, obtained from hepatitis carrying blood, 5 or by genetic engineering techniques or by chemical synthesis.

Measles vaccine: a vaccine comprising the whole or part of a virus grown in a cultured chick embryo cells or embryonated egg, or a protective antigen obtained by genetic 10 engineering or chemical synthesis.

Rubella vaccine: a vaccine comprising the whole or part of a virus grown in cultured chick embryo cells or embryonated egg, or a protective antigen obtained by genetic engineering techniques or chemical synthesis.

15 Mumps vaccine: a vaccine comprising the whole or part of a virus grown in cultured rabbit cells or embryonated egg, or a protective antigen obtained by genetic engineering techniques or chemical synthesis.

Mixed vaccine of measles, rubella and mumps: a 20 vaccine produced by mixing measles, rubella and mumps vaccines.

Rotavirus vaccine: a vaccine comprising the whole or part of a virus grown in cultured MA 104 cells or isolated from the patient's feces, or a protective antigen obtained by 25 genetic engineering techniques or chemical synthesis.

Mycoplasma vaccine: a vaccine comprising the whole or part of mycoplasma cells grown in a liquid culture medium for mycoplasma or a protective antigen obtained by genetic engineering techniques or chemical synthesis.

30 Those conditions for which effective prevention may be achieved by the present method will be obvious to the skilled artisan.

The vaccine preparation compositions of the present invention can be prepared by mixing the above illustrated antigens and/or vaccines with LT-A/CT-B at a desired ratio. Pyrogens or allergens should naturally be removed as
5 completely as possible. The antigen preparation of the present invention can be used by preparing the antigen per se and the LT-A/CT-B separately or together.

Further, the present invention encompasses a kit comprising an effective amount of antigen and an adjuvant
10 effective amount of LT-A/CT-B. In use, the components of the kit can either first be mixed together and then administered or the components can be administered separately within a short time of each other.

The vaccine preparation compositions of the present
15 invention can be combined with either a liquid or solid pharmaceutical carrier, and the compositions can be in the form of tablets, capsules, powders, granules, suspensions or solutions. The compositions can also contain suitable preservatives, coloring and flavoring agents, or agents that
20 produce slow release. Potential carriers that can be used in the preparation of the pharmaceutical compositions of this invention include, but are not limited to, gelatin capsules, sugars, cellulose derivations such as sodium carboxymethyl cellulose, gelatin, talc, magnesium stearate, vegetable oil
25 such as peanut oil, etc., glycerin, sorbitol, agar and water. Carriers may also serve as a binder to facilitate tableting of the compositions for convenient administration.

6. EXAMPLES

30 The following examples are presented for purposes of illustration only and are not intended to limit the scope of the invention in any way.

6.1. PRODUCTION OF HYBRID TOXINS

For construction of some plasmids, new restriction enzyme cleavage sites were introduced by site-directed mutagenesis to facilitate subcloning of gene fragments.

- 5 Oligonucleotide primers used for this purpose, and for the amplification of CT-A from pCT2, are detailed below. Hybrid plasmids were verified by sequencing.

Construction of the CT-A/LT-B Hybrid

- 10 A hybrid plasmid containing the wild type CT, designated pCT2, was created by subcloning a 5.1 kb fragment from the plasmid pBB6, which contains both the zot and ctx genes from the classical Inaba V. cholerae strain 569B, (a generous gift from J. Kaper) into pUC19. PCR was performed
- 15 with primers designed to amplify the ctxa gene using pCT2 as a template (primers 1 and 2, listed below). PCR product was digested with EcoR1 and SstI, which cleaved restriction sites at the ends of ctxa introduced by the PCR primers, and ligated into pUC18 to create pCTA3. A gene fragment encoding
- 20 LT-B from pCS96, a pUC18 based plasmid containing the LT operon (International Patent Publication WO99/47164, International Patent Publication WO99/47165), was then introduced by restriction digest with Sst and HindIII, yielding a CT-A/LT-B construct.

25

Construction of the LT-A/CT-B Hybrid

- pCT2 was mutagenized to introduce a new SstI site at the end of the ctxa gene which parallels an existing site in the LT gene (primers 2 and 3). A restriction digest with
- 30 SstI and HindIII released the ctxb gene, which as then ligated into pUC18 to form pCTB5. PCS96 was digested with SstI to release a fragment containing the lta gene, which was

then ligated into SstI-digested pCTB5, producing an LT-A/CT-B construct. Attempts to purify CT from a plasmid containing the introduced SstI site, which changed a threonine to an alanine in the B subunit, proved problematic. The alanine
5 was changed back to the wild type threonine in both the CT expressing plasmid and the LT-A/CT-B plasmid (primers 4, 5, 6 and 7).

Construction of Mutants

10 The various mutations described above were introduced using the QuickChange site-directed mutagenesis kit (Stratagene). The oligonucleotide primers used are shown below. Pfu DNA polymerase is used in the PCR reaction to extend primers and replicate the plasmid template. After
15 completion of the reaction, samples are treated with DpnI, which selectively digests the parental DNA template based on dam methylation. The remaining DNA samples were then transformed into *E. coli* XL-1 Blue supercompetent cells and then into *E. coli* JM83 *ara Δlac-proAB rpsLφ80ΔlacZ ΔM15* for
20 expression and protein purification. Each mutation was confirmed by DNA sequencing.

Primer 1 5'-GGCTGTGGGTAGAATTCAAACGGGG-3'

Primer 2 5'-GAGGAGCTCCATGTGCATATGCTG-3'

Primer 3 5'-CAGCAATATGCACATGGAGCTCCTC-3'

25 Primer 4 5'-CAGCATATGCACATGGAACACCTC-3'

Primer 5 5'-GAGGTGTTCCATGTGCATATGCTG-3'

Primer 6 5'-CCTCTCTATGTGCATACGGAACACCTC-3'

Primer 7 5'-GAGGTGTTCCGTATGCACATAGAGAGC-3'

Primer 8 5'-CCGGGTTGTGGGAATGCTCCAGGATCCTCGATCAG-3'

30

Purification of Hybrid Toxins

All toxins were purified from cultures grown overnight in a 10 liter fermenter of Evan's medium supplemented with 100 µg of ampicillin per ml. The cells were harvested by centrifugation, resuspended in TEAN (0.2 M NaCl, 0.05 M Tris, 0.001 M EDTA, 0.003 M NaN₃, pH 7.5), lysed by French press. Cell lysate was dialyzed against TEAN overnight at 4°C, clarified by centrifugation, and subjected to chromatography on designated immobilized D-galactose (Acros Organics, Fisher) in TEAN. Each purified toxin was characterized by SDS-PAGE.

6.2. LT-A/CT-B EXHIBITS REDUCED ENTEROTOXICITY

In order to evaluate the enterotoxicity of these hybrids, a patent mouse assay was performed wherein groups of mice were orally inoculated with CT, LT, LT(R192G), LT-A(R192G)/CT-B, CT-A/LT-B, or LT-A/CT-B at 5, 25, or 125 µg (50 and 250 µg in the cases of LT(R192G) and LT-A(R192G)/CT-B).

For the patent mouse cell assay, mice (in triplicate) were inoculated with the indicated compounds after being deprived of food the previous night. The mice were sacrificed after three hours by CO₂ inhalation. The entire intestine from duodenum to anus was then carefully removed to retain any accumulated fluid; residual mesentary was removed prior to weighing. The carcass was weighed separately, and a gut to carcass ratio was calculated for each animal.

Based on the previous findings of others, it was anticipated that LT-A/CT-B and CT-A/LT-B would have undiminished enterotoxicity when compared to native LT and

native CT since the A-subunits of the hybrid toxins were unaltered. As shown in Figure 2, it was unexpectedly found that LT-A/CT-B and LT-A(R192G)/CT-B have significantly reduced enterotoxicity in the patent mouse assay when compared to native LT, native CT, LT(R192G) or the alternate hybrid CT-A/LT-B, and that LT-A(R192G)/CT-B has reduced toxicity with respect to LT-A/CT-B.

6.3. LT-A/CT-B EXHIBITS REDUCED ENZYMATIC ACTIVITY

10 In order to more fully evaluate this unexpected finding, LT-A/CT-B was evaluated for the ability to induce cAMP in cultured Caco2 cells. Intracellular cAMP accumulation was determined as described by Grant et al. (Grant et al. 1994, Infection and Immunity 62:4270-4278). Cells are seeded
15 in 6 well cluster plates (Corning Costar, Cambridge, MA) and grown to near confluence. Prior to addition of toxins, cells are incubated in MEM containing 1% FBS and 1 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma) for 30 minutes at 37°C in 5% CO₂. One µg of each trypsin-cleaved toxin is added to each
20 well of cells. At 1, 2, 3, and 4 hours after toxin addition, cells are washed twice with cold PBS. Intracellular cAMP is extracted by adding 0.4 mL of 0.1 N HCl to each well and incubating at room temperature for 15 minutes. cAMP is detected using an ELISA based low pH cAMP kit (R&D Systems,
25 Minneapolis, MN). Activity in this assay has been shown to be directly correlated with the toxicity of these molecules.

As shown Figure 3, despite having an unaltered, intact A-subunit, the hybrid molecule LT-A/CT-B induced significantly less cAMP in this assay when compared to native
30 LT, native CT, or the alternate hybrid CT-A/LT-B.

6.4. LT-A/CT-B EXHIBITS ADJUVANTICITY

Comparison of LT-A/CT-B with native LT, native CT, and CT-A/LT-B for the ability to induce antigen-specific
5 serum IgG following mucosal immunization with Tetanus Toxoid
in conjunction with either LT-A/CT-B, native LT, native CT,
or CT-A/LT-B was conducted as follows. Groups of BALB/c mice
were immunized intranasally once per week for three weeks.
Intranasal immunization consists of 8 μ l of the antigen
10 preparation, (10 μ g of TT with 5 μ g of adjuvant). Eight μ l
aliquots were introduced into one nostril while the mice were
under light anesthesia. One week after the third
immunization, animals were sacrificed, serum was obtained by
cardiac puncture and spleens were collected for T cell in
15 vitro antigen restimulation assay.

Antigen-specific antibody responses were determined
by ELISA. Reagents and antisera for the ELISA were obtained
from Sigma unless indicated otherwise. Serum samples were
serially diluted 1:2 in PBS-0.05% Tween 20 and added to 96-
20 well plates precoated with 10 μ g of TT per well. Anti-TT IgG
levels were determined with rabbit antiserum against mouse
IgG conjugated to alkaline phosphatase. Reactions were
stopped with 3 N NaOH, and the absorbance at 405 nm
determined spectrophotometrically. Concentrations of IgG were
25 determined using a standard curve generated with purified
mouse myeloma proteins. As shown in Figure 4, LT-A/CT-B was
as effective as native LT, native CT, or CT-A/LT-B in
inducing antigen-specific antibody responses in immunized
animals, despite the significantly reduced enterotoxicity and
30 enzymatic activity of LT-A/CT-B when compared to native LT,
native CT, or CT-A/LT-B.

For in vitro antigen restimulation assays, BALB/c mice immunized as described above were sacrificed, and the spleens removed and pooled for each group. Spleens were homogenized through a cell dissociation sieve (Sigma),
5 pelleted and resuspended in RPMI 1640 with 1% fetal bovine serum (FBS). Mononuclear cells were purified by gradient density centrifugation using Histopaque-1119 (Sigma), washed and resuspended in complete RPMI 1640 containing 10% FBS, 100 μ g streptomycin sulfate and 0.25 μ g amphotericin B (Gibco
10 BRL), and 100 units penicillin G sodium per ml. Purified mononuclear cells were enumerated and tested for viability by Trypan blue exclusion. 1×10^7 mononuclear cells were added to each well in a 12 well plate containing 1×10^6 cells per well of incomplete Freund's adjuvant-elicited peritoneal
15 macrophages obtained from naive mice and incubated with the antigen for an hour prior to addition of mononuclear cells. One, three, and five days post culture, supernatants were collected and kept at -20C until assayed. Cytokines in the culture supernatants were detected by murine ELISA kits
20 (PharMingen San Diego, CA).

As seen in Figure 5, LT-A/CT-B was as effective as native LT, and more effective than native CT, or CT-A/LT-B in inducing antigen-specific Th1-type cytokines; specifically, IFN-gamma, in mononuclear cells from the spleens of immunized
25 animals, despite the significantly reduced enterotoxicity and enzymatic activity of LT-A/CT-B when compared to native LT, native CT, or CT-A/LT-B.

As seen in Figure 6, LT-A/CT-B was more effective than native LT, native CT, or CT-A/LT-B in inducing antigen-
30 specific Th2-type cytokines; specifically, IL-6, in mononuclear cells from the spleens of immunized animals, despite the significantly reduced enterotoxicity and

enzymatic activity of LT-A/CT-B when compared to native LT, native CT, or CT-A/LT-B.

Although the invention is described in detail with reference to specific embodiments thereof, it will be
5 understood that variations which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings.
10 Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosure of which are incorporated by reference in their entireties.

15

20

25

30

WHAT IS CLAIMED IS:

1. A composition comprising a LT-A/CT-B hybrid enterotoxin holotoxin, which holotoxin has immunologic
5 adjuvant activity and is substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the patent mouse assay.
2. The composition of claim 1 in which the
10 holotoxin is recombinantly produced.
3. The composition of claim 1 in which the LT-A subunit of the LT-A/CT-B hybrid enterotoxin holotoxin is a mutant LT-A.
15
4. The composition of claim 3 in which the mutant LT-A, if it were associated with LT-B would form a mutant holotoxin that is substantially less toxic than native heat-labile enterotoxin holotoxin as measured in the patent mouse
20 assay.
5. A preparation comprising an antigen in combination with the composition according to claim 1.
- 25 6. The preparation according to claim 5, in which the antigen is selected from the group of antigens consisting of bacterial, fungal, protozoal, viral, helmenthal and other microbial pathogenic antigens.
- 30 7. The preparation according to claim 6, in which the antigen is selected from the group consisting of *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria*

gonorrhoea, *Neisseria meningitidis*, *Corynebacterium*
diphtheriae, *Clostridium botulinum*, *Clostridium perfringens*,
Clostridium tetani, *Haemophilus influenzae*, *Klebsiella*
pneumoniae, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*,
5 *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*,
Pseudomonas aeruginosa, *Campylobacter* (*Vibrio*) *fetus*,
Campylobacter jejuni, *Aeromonas hydrophila*, *Bacillus cereus*,
Edwardsiella tarda, *Yersinia enterocolitica*, *Yersinia pestis*,
Yersinia pseudotuberculosis, *Shigella dysenteriae*, *Shigella*
10 *flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Treponema*
pallidum, *Treponema pertenue*, *Treponema caratense*, *Borrelia*
vincentii, *Leptospira icterohemorrhagiae*, *Mycobacterium*
tuberculosis, *Toxoplasma gondii*, *Pneumocystis carinii*,
Francisella tularensis, *Brucella abortus*, *Brucella suis*,
15 *Brucella melitensis*, *Mycoplasma* spp., *Rickettsia prowazekii*,
Rickettsia tsutsugumushi, *Chlamydia* spp., *Helicobacter*
pylori, *Coccidioides immitis*, *Aspergillus fumigatus*, *Candida*
albicans, *Blastomyces dermatitidis*, *Cryptococcus neoformans*,
Histoplasma capsulatum, *Entamoeba histolytica*, *Trichomonas*
20 *tenax*, *Trichomonas hominis*, *Trichomonas vaginalis*,
Trypanosoma gambiense, *Trypanosoma rhodesiense*, *Trypanosoma*
cruzi, *Leishmania donovani*, *Leishmania tropica*, *Leishmania*
braziliensis, *Pneumocystis pneumonia*, *Enterobius*
vermicularis, *Trichuris trichiura*, *Ascaris lumbricoides*,
25 *Trichinella spiralis*, *Strongyloides stercoralis*, *Schistosoma*
japonicum, *Schistosoma mansoni*, *Schistosoma haematobium*,
variola virus, *vaccinia virus*, *cowpox virus*, *varicella-zoster*
virus, *Herpes Simplex virus 1*, *Herpes Simplex virus 2*,
influenza viruses, *parainfluenza virus*, *mumps*, *measles*,
30 *respiratory syncytial virus*, *rubella*, *Hepatitis A virus*,
Hepatitis B virus, *Hepatitis C virus*, *Hepatitis E virus*, and
Non-A/Non-B Hepatitis virus antigens.

8. A composition useful in producing an immune response to a pathogen in a host comprising an admixture of an effective amount of an antigen and an adjuvant effective amount of the composition according to claim 1.

5

9. A kit useful in producing an immune response in a host to a pathogen comprising two components: (a) an effective amount of antigen and (b) an adjuvant effective amount of an LT-A/CT-B hybrid enterotoxin holotoxin, which
10 holotoxin has immunologic adjuvant activity and is substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the patent mouse assay.

10. A method of creating or sustaining an immune
15 response to an antigen in a host comprising administering an admixture of an effective amount of an antigen and an adjuvant effective amount of an LT-A/CT-B hybrid enterotoxin holotoxin, which holotoxin has immunologic adjuvant activity and is substantially less toxic than native *E. coli* heat-
20 labile enterotoxin holotoxin as measured in the patent mouse assay, in an orally acceptable pharmaceutical carrier.

11. The method of claim 10 where a serum response is produced.

25

12. The method of claim 10 where a cell-mediated immune response is produced.

13. The method of claim 10 where a mucosal
30 response is produced.

14. The method of claim 10 further comprising administering a subsequent boost of the antigen.

15. The method of claim 10 wherein the antigen is
5 derived from the group consisting of bacterial, viral, protozoal, fungal, helminthal, and other microbial pathogens.

16. The method of claim 10 wherein the administration is mucosal administration.

10

17. A method of inducing an immune response to an antigen in a host comprising administering an effective amount of an antigen in conjunction with an adjuvant effective amount of an LT-A/CT-B hybrid enterotoxin
15 holotoxin, which holotoxin has immunologic adjuvant activity and is substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the patent mouse assay.

20 18. The method of claim 16 in which the antigen and the holotoxin are administered simultaneously.

19. The method of claim 16 in which the antigen
and holotoxin are administered separately within a short time
25 of each other.

20. A method of inducing an immune response against an enterotoxic bacterial organism comprising administering an adjuvant effective amount of an LT-A/CT-B
30 hybrid enterotoxin holotoxin, which holotoxin has immunologic adjuvant activity and is substantially less toxic than native *E. coli* heat-labile enterotoxin holotoxin as measured in the

patent mouse assay, as a component of a vaccine directed against the enterotoxigenic bacterial organism.

21. The method of claim 19 wherein the enterotoxigenic
5 bacterial organism is selected from the group consisting of enterotoxigenic bacterial organisms which express a cholera-like toxin.







22. The method of claim 19 wherein the enterotoxigenic
10 bacterial organism is selected from the group consisting of *Escherichia* spp. and *Vibrio* spp.

15


20


25

30




Patent Mouse Assay







Serum anti-TT IgG



TT-specific Cytokine Response



TT-specific Cytokine Response



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 November 2001 (29.11.2001)

PCT

(10) International Publication Number
WO 01/89456 A3

- (51) International Patent Classification⁷: **A61K 39/00**, 39/385, 39/116, 39/108, 39/106, G01N 33/53
- (21) International Application Number: PCT/US01/16542
- (22) International Filing Date: 21 May 2001 (21.05.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/205,969 19 May 2000 (19.05.2000) US
- (71) Applicant (for all designated States except US): **THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND** [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **CLEMENTS, John, D.** [US/US]; 7900 Jeanette Place, New Orleans, LA 98021 (US).
- (74) Agents: **BALDWIN, Geraldine, F. et al.**; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
11 April 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/89456 A3

(54) Title: HYBRID LT-A/CT-B HOLOTOXIN FOR USE AS AN ADJUVANT

(57) Abstract: The present invention provides a novel composition which is a hybrid heat labile enterotoxin comprising the A-subunit of the heat labile toxin of *Escherichia coli* (LT-A) and the B-subunit of the cholera enterotoxin *Vibrio cholerae* (CT-B). The hybrid toxin is designated LT-A/CT-B. The LT-A subunit, the CT-B subunit, or both subunits of the hybrid toxin may be mutant subunits *e.g.*, differing from wild-type subunits by amino acid substitutions, deletions or additions. Also provided are methods of using the novel LT-A/CT-B comprising compositions of the invention as adjuvants for vaccines, methods of making the LT-A/CT-B hybrid holotoxin, and kits.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/16542

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 39/00, 39/385, 39/116, 39/108, 39/106; G01N 33/53 US CL : 424/184.1, 192.1, 193.1, 197.11, 203.1, 241.1, 261.1; 435/975 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/184.1, 192.1, 193.1, 197.11, 203.1, 241.1, 261.1; 435/975 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST, DIALOG, MEDLINE, BIOSIS, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 6,149,919 A (DOMENIGHINI et al.) 21 November 2000, see entire document.	1-22
Y	US 6,019,973 A (HOLMGREN et al.) 01 February 2000, see entire document.	1-22
A	RODIGHIERO et al. Structural Basis for the Differential Toxicity of Cholera Toxin and Escherichia coli Heat-labile Enterotoxin. J. Biol. Chem. February 1999, Vol. 264, No. 7, pages 3962-3969, see entire document.	1-22
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
E earlier document published on or after the international filing date	*Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search		Date of mailing of the international search report
31 OCTOBER 2001		31 DEC 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer JENNIFER GRASER For
Facsimile No. (703) 305-3230		Telephone No. (703) 308-0196